Tetanus D013742

Diseases [C] » Infections [C01] » Bacterial Infections and Mycoses » Bacterial Infections » Gram-Positive Bacterial Infections » Clostridium Infections » Tetanus

Description

A disease caused by tetanospasmin, a powerful protein toxin produced by CLOSTRIDIUM TETANI. Tetanus usually occurs after an acute injury, such as a puncture wound or laceration. Generalized tetanus, the most common form, is characterized by tetanic muscular contractions and hyperreflexia. Localized tetanus presents itself as a mild condition with manifestations restricted to muscles near the wound. It may progress to the generalized form.   MeSH

Hierarchy View

View MeSH Tree View ICD-10 Tree

Phase 4 Indicated Drugs (18)

acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia)

attenuated measles vaccine - Edmonston strain (rubeovax)

Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine (Kinrix)

diphtheria-tetanus-acellular pertussis-inactivated poliovirus-haemophilus influenzae b conjugate-hepatitis b vaccine (Pediarix)

diphtheria, tetanus and whole cell pertussis vaccine (Boostrix)

diphtheria toxoid

haemophilus influenzae type b conjugate vaccine (HibTITER)

hepatitis a vaccine, inactivated (vaqta)

hepatitis b vaccine (recombinant) (Recombivax)

Inactivated polio virus - Enhanced (IPOL)

Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (MenQuadfi)

pneumococcal 13-valent conjugate vaccine (prevnar 13)

quinvaxem

technetium tc-99m pentetate kit (renotec)

Tetanus and diphtheria toxoids adsorbed (Decavac)

tetanus immunoglobulin (Bastet)

tetanus toxoid

trianrix

Phase 3 Indicated Drugs (25)

10-valent Pneumococcal Conjugate Vaccine (Pneumosil)

acellular pertussis vaccine (ACEL-IMUNE\T)

Bivalent group A and C meningococcal vaccine (Menomune-A/C)

bivalent oral polio vaccine (bopv), type 1 and type 3 (BOPV)

diphtheria, tetanus, and poliovirus vaccine

diphtheria-tetanus-whole cell pertussis-inactivated poliovirus-haemophilus influenzae b conjugate-hepatitis b vaccine

glyco-conjugate neisseria meningitidis serogroup c vaccine

haemophilus influenzae type b-neisseria meningitidis serogroups c and y-tetanus-toxoid conjugate vaccine

hib-menac

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil)

human rotavirus, live attenuated (Rotarix)

inactivated influenza vaccine

inactivated poliovirus type 2 vaccine

live attenuated varicella vaccine (Varivax)

measles, mumps, and rubella vaccine (MMR)

Measles, Mumps and Rubella Vaccine, Live (Priorix)

measles, mumps, rubella, varicella vaccine (ProQuad)

meningococcal conjugate vaccine (Menveo)

menitorix

Monovalent group C meningococcal vaccine (Menomune-C)

pneumococcal 7-valent conjugate vaccine (Prevnar)

polio, inactivated poliovirus vaccine (Salk Vaccine)

polyribosil-ribitol-phosphate vaccine

rotavirus vaccine, live, oral, pentavalent (Rotateq)

tritanrix-hepb

Phase 2 Indicated Drugs (10)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23)

aluminum hydroxide (Gaviscon)

gc3111

gsk2036874a

gsk217744

gsk2202083a

menjugate

multi-valent pneumococcal conjugate vaccine

polysaccharide diphtheria toxoid conjugate vaccine

sp0202-vii pneumococcal conjugate vaccine

Phase 1 Indicated Drugs (1)

chlorpromazine (Thorazine)


Organization Involved with Phase 4 Indications (21)

Bandim Health Project

Crucell

Danish Council for Development Research

Erasmus University Rotterdam

GlaxoSmithKline

Government of Norway

Grifols

Korea University

Leiden University

LG

Medical Research Council, The Gambia

National Institute of Allergy and Infectious Diseases (NIAID)

Northwell Health

Novo Nordisk

Sanofi

Sanofi-Aventis

Shantha Biotechnics Limited

Statens Serum Institut

Swedish Institute for Infectious Disease Control

Tel Aviv University

University of Liege

Organization Involved with Phase 3 Indications (12)

Boryung Pharmaceutical Company

Catholic University of Korea

Eulji University

GCAM Inc.

Government of China

Government of Vietnam

Institut Pasteur

Merck

Mitsubishi Tanabe

Novartis

Osaka University

Universidad Autonoma de Barcelona

Organization Involved with Phase 2 Indications (4)

Green Cross Corporation

Herbert Irving Comprehensive Cancer Center

National Cancer Institute (NCI)

University of Tehran

Organization Involved with Phase 1 Indications (6)

Axio Research Corporation

Centers for Disease Control and Prevention (CDC)

Emory University

Ghent University

Hammond Clinical Trial Consulting, LLC

RMD Insight, LLC

Organization Involved with Other Experimental Indications (3)

Epicentre

Vabiotech

Vietstar Biomedical Research

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.